{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:30:09Z","timestamp":1778963409954,"version":"3.51.4"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1007\/s11908-003-0011-0","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T02:52:37Z","timestamp":1180061557000},"page":"329-336","source":"Crossref","is-referenced-by-count":27,"title":["Fluoroquinolones in the treatment of meningitis"],"prefix":"10.1007","volume":"5","author":[{"given":"Philippe","family":"Cottagnoud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin G.","family":"T\u00e4uber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"11_CR1","first-page":"6","volume":"4","author":"AR Tunkel","year":"2002","unstructured":"Tunkel AR, Scheld WM: Treatment of bacterial meningitis. Curr Infect Dis Rep 2002, 4:6\u201316. This state-of-the-art review provides an excellent overview of the newest therapeutic modalities of bacterial meningitis.","journal-title":"Curr Infect Dis Rep"},{"key":"11_CR2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1056\/NEJMoa021334","volume":"347","author":"J Gans de","year":"2002","unstructured":"de Gans J, van de Beek D: Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002, 347:1549\u20131556. This prospective randomized study shows the benefit of addition of dexamethasone to the standard regimen in bacterial meningitis in adults.","journal-title":"N Engl J Med"},{"key":"11_CR3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1128\/AAC.39.9.2158","volume":"39","author":"C Cabellos","year":"1995","unstructured":"Cabellos C, Martinez-Lacasa J, Martos A, et al.: Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis. Antimicrob Agents Chemother 1995, 39:2158\u20132160.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/21202","volume":"399","author":"R Novak","year":"1999","unstructured":"Novak R, Henriques B, Charpentier E, et al.: Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999, 399:590\u2013593.","journal-title":"Nature"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1086\/315216","volume":"181","author":"JA McCullers","year":"2000","unstructured":"McCullers JA, English BK, Novak R: Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000, 181:369\u2013373.","journal-title":"J Infect Dis"},{"key":"11_CR6","first-page":"227","volume":"29","author":"HC Neu","year":"1994","unstructured":"Neu HC: Major advances in antibacterial quinolone therapy. Adv Pharmacol 1994, 29:227\u2013262.","journal-title":"Adv Pharmacol"},{"key":"11_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1098-1128(199609)16:5<433::AID-MED3>3.0.CO;2-W","volume":"16","author":"TD Gootz","year":"1996","unstructured":"Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance and clinical aspects. Med Res Rev 1996, 16:433\u2013436.","journal-title":"Med Res Rev"},{"key":"11_CR8","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1021\/jm00153a015","volume":"29","author":"JM Domagala","year":"1986","unstructured":"Domagala JM, Hanna LD, Heifetz CL, et al.: New structureactivity relationships of the quinolone antibacterials using the target enzyme: the development and application of a DNA gyrase assay. J Med Chem 1986, 29:394\u2013404.","journal-title":"J Med Chem"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.28.4.581","volume":"28","author":"JS Wolfson","year":"1985","unstructured":"Wolfson JS, Hooper DC: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985, 28:581\u2013586.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR10","first-page":"47","volume-title":"International Telesymposium on Quinolones","author":"TP Culberston","year":"1989","unstructured":"Culberston TP, Domagala JM, Hagen SE, et al.: Structureactivity relationship of the quinolone antibacterials: the nature of the C7-side chain. In International Telesymposium on Quinolones. Edited by Fernandes PB, Barcelona: JR Prous Science Publishers; 1989:47\u201371."},{"key":"11_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0092-8674(90)90172-B","volume":"63","author":"J Kato","year":"1990","unstructured":"Kato J, Nishimura Y, Niki H, et al.: New topoisomerase essential for chromosome segregation in E. coli. Cell 1990, 63:393\u2013404.","journal-title":"Cell"},{"key":"11_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0092-8674(83)90140-X","volume":"34","author":"R Menzel","year":"1987","unstructured":"Menzel R, Gelbert M: Regulation of genes for E. coli DNA gyrase: homeostatic control of DNA supercoiling. Cell 1987, 34:105\u2013113.","journal-title":"Cell"},{"key":"11_CR13","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1073\/pnas.74.11.4772","volume":"74","author":"M Gellert","year":"1977","unstructured":"Gellert M, Mizuuchi D, O\u2019Dea MH, et al.: Nalidixic acid resistance. A second genetic character involved in DNA gyrase activity. Proc Natl Acad Sci U S A 1977, 74:4772\u20134776.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR14","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1073\/pnas.74.11.4767","volume":"74","author":"A Sugino","year":"1977","unstructured":"Sugino A, Peebles CL, Kruezer KN, Cozzarelli NR: Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme. Proc Natl Acad Sci U S A 1977, 74:4767\u20134771.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11_CR15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.genet.30.1.79","volume":"30","author":"WM Huang","year":"1996","unstructured":"Huang WM: Bacterial diversity based on type II DNA topoisomerase genes. Ann Rev Genet 1996, 30:79\u2013107.","journal-title":"Ann Rev Genet"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"24481","DOI":"10.1016\/S0021-9258(20)80551-1","volume":"268","author":"H Peng","year":"1991","unstructured":"Peng H, Marians K: E. coli topoisomerase IV: purification, characterization, subunit structure and subunit interactions. J Biol Chem 1991, 268:24481\u201324490.","journal-title":"J Biol Chem"},{"key":"11_CR17","first-page":"749","volume-title":"E. coli and Salmonella Cellular and Molecular Biology","author":"KJ Marians","year":"1996","unstructured":"Marians KJ: Replications fork progression. In E. coli and Salmonella Cellular and Molecular Biology. Edited by Neidhart FC, Washington DC: American Society of Microbiology; 1996:749\u2013763."},{"key":"11_CR18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1073\/pnas.82.2.307","volume":"82","author":"L Shen","year":"1985","unstructured":"Shen L, Pernet AG: Mechanism of inhibition of DNA gyrase by analogs of nalidixic acid: the target of the drugs is DNA. Proc Natl Acd Sci U S A 1985, 82:307\u2013311.","journal-title":"Proc Natl Acd Sci U S A"},{"key":"11_CR19","doi-asserted-by":"crossref","first-page":"27668","DOI":"10.1074\/jbc.273.42.27668","volume":"273","author":"AB Khodursky","year":"1998","unstructured":"Khodursky AB, Cozzarelli NR: The mechanisms of inhibition of topoisomerase IV by quinolone antibacterials. J Biol Chem 1998, 273:27668\u201327677.","journal-title":"J Biol Chem"},{"key":"11_CR20","doi-asserted-by":"crossref","first-page":"17879","DOI":"10.1074\/jbc.273.28.17879","volume":"273","author":"VE Anderson","year":"1998","unstructured":"Anderson VE, Gootz TD, Osheroff N: Topoisomerase IV catalysis and the mechanism of quinolone action. J Biol Chem 1998, 273:17879\u201317885.","journal-title":"J Biol Chem"},{"key":"11_CR21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/AAC.28.4.581","volume":"28","author":"JS Wolfson","year":"1985","unstructured":"Wolfson JS, Hooper DC: The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985, 28:581\u2013586.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR22","first-page":"219","volume-title":"Microbiology-1986","author":"GM Eliopoulos","year":"1986","unstructured":"Eliopoulos GM: In vitro activity of new quinolone antimicrobial agents. In Microbiology-1986. Edited by Leive L. Washington DC: American Society for Microbiology; 1986:219\u2013221."},{"key":"11_CR23","first-page":"900","volume-title":"Antibiotics in Laboratory Medicine","author":"B Wiedemann","year":"1996","unstructured":"Wiedemann B, Grimm H: Susceptibility to antibiotics: species incidence and trends. In Antibiotics in Laboratory Medicine. Edited by Lorian V. Baltimore: Williams & Wilkins; 1996:900\u20131168."},{"key":"11_CR24","unstructured":"Morisini MI, Loza E, Almaraz F, et al.: In vitro activity of garenoxacin (BMS-284756) against prospectively collected Spanish pneumoniae isolates S. [abstract E-62.] Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27\u201330, 2002."},{"key":"11_CR25","unstructured":"Jones RN, Mutnick A, Biedenbach D: Garenoxacin (BMS 284756) activity against 8686 S. pneumoniae (SPN) including tentative susceptibility testing criteria [abstract E-58]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27\u201330, 2002."},{"key":"11_CR26","unstructured":"Kelly LM, Smith K, Jacobs M, Appelbaum P: Anti-pneumococcal activity of a new quinolone, DK-507k, compared to eleven other agents by MIC methodology [abstract E-572]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27\u201330, 2002."},{"key":"11_CR27","unstructured":"Ling G, Patel M, Bupte S, et al.: Time kill analysis of the antipneumococcal activity of two new quinolones, WCK 771A and WCK 919, compared to five other quinolones [abstract F-559]. Paper presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27\u201330, 2002."},{"key":"11_CR28","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1128\/AAC.43.5.1310","volume":"43","author":"PL Ho","year":"1999","unstructured":"Ho PL, Que TL, Tsang DN, et al.: Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999, 43:1310\u20131313. This paper is an important epidemiologic study revealing the increase in quinolone-resistant pneumococci.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR29","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.43.8.2000","volume":"43","author":"E Pestova","year":"1999","unstructured":"Pestova E, Beyer R, Ciancotto NP, et al.: Contribution of topoisomerase IV and gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones. Antimicrob Agents Chemother 1999, 43:2000\u20132004.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR30","unstructured":"Vasquez J, de la Fuente L, Gimenez MJ, et al.: In vitro activity of gemifloxacin and 13 other antimicrobials against 400 Spanish isolates of Neisseria meningitidis collected between 1998\u20131999 [abstract 132]. Paper presented at 3rd European Congress of Chemotherapy. Madrid. May 7-10, 2000."},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1128\/AAC.39.11.2577","volume":"39","author":"JM Blondeau","year":"1995","unstructured":"Blondeau JM, Yaschuk Y: In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol and rifampicin against fully susceptible and moderately penicillin-resistant Neisseria meningitidis. Antimicrob Agents Chemother 1995, 39:2577\u201325769.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0732-8893(01)00289-9","volume":"41","author":"SS Richter","year":"2001","unstructured":"Richter SS, Gordon KA, Rhomberg PR, et al.: Neisseria meningitidis with decreased susceptibility to penicillin: Report from Sentry antimicrobial surveillance program, North America, 1998\u20131999. Diag Microb Infect Dis 2001, 41:83\u201388.","journal-title":"Diag Microb Infect Dis"},{"key":"11_CR33","first-page":"1166","volume":"44","author":"TR Schultz","year":"2000","unstructured":"Schultz TR, Tapsall JW, White PA, Newton PJ: An invasive isolate of Neisseria meningitidis showing decreased susceptibility to quinolones. Antimicrob Agents Chemother 2000, 44:1166.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jac\/47.5.681","volume":"47","author":"F Garcia-Garrote","year":"2001","unstructured":"Garcia-Garrote F, Cercenado E, Martin-Pedroviejo J, et al.: Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens. J Antimicrob Chemother 2001, 47:681\u2013684.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0732-8893(01)00224-3","volume":"39","author":"DJ Biedenbach","year":"2001","unstructured":"Biedenbach DJ, Jones RN, Pfaller MA, The Sentry Participant Groups (Americas and Europe): Activity of BMS 284756 against 2681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: report from the Sentry Antimicrobial Surveillance program (2000) in Europe, Canada and the United States. Diagn Microb Infect Dis 2001, 39:245\u2013250.","journal-title":"Diagn Microb Infect Dis"},{"key":"11_CR36","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1128\/AAC.46.3.904-908.2002","volume":"46","author":"M Tanaka","year":"2002","unstructured":"Tanaka M, Yamazaki E, Megumi, et al.: In vitro antibacterial activities of DQ-113, a potent quinolone-against clinical isolates. Antimicrob Agents Chemother 2002, 46:904\u2013908.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR37","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1128\/AAC.45.11.3226-3228.2001","volume":"45","author":"F Marco","year":"2001","unstructured":"Marco F, Garcia-de-Lomas J, Garcia-Rey C, et al., and the Spanish Surveillance Group for Respiratory Pathogens: Antimicrobial susceptibility of 1730 Haemophilus influenzae respiratory tract isolates in Spain in 1998\u20131999. Antimicrob Agents Chemother 2001, 45:3226\u20133228.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000007234","volume":"45","author":"MP Montanari","year":"1999","unstructured":"Montanari MP, Mingoia M, Marchetti F, Varaldo PE: In vitro activity of levofloxacin against gram-positive bacteria. Chemotherapy 1999, 45:411\u2013417.","journal-title":"Chemotherapy"},{"key":"11_CR39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/45.1.31","volume":"45","author":"JAA Hoogkamp-Korstanje","year":"2000","unstructured":"Hoogkamp-Korstanje JAA, Reolofs-Willemse J: Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000, 45:31\u201339.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0732-8893(02)00433-9","volume":"44","author":"KVI Rolston","year":"2002","unstructured":"Rolston KVI, Frisbee-Hume S, LeBlanc BM, et al.: Antimicrobial activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diag Microbiol Infect Dis 2002, 44:187\u2013194.","journal-title":"Diag Microbiol Infect Dis"},{"key":"11_CR41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/AAC.41.1.60","volume":"41","author":"C Michelet","year":"1997","unstructured":"Michelet C, Avril JL, Arvieux C, et al.: Comparative activities of new fluoroquinolones, alone and in combination with amoxicillin, trimethoprim-sulfamethoxale, or rifampicin, against intracellular Listeria monocytogenes. Antimicrob Agents Chemother 1997, 41:60\u201365.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0732-8893(94)90014-0","volume":"20","author":"CE Cherubin","year":"1994","unstructured":"Cherubin CE, Stratton CW: Assessment of the bactericidal activity of sparfloxacin, ofloxaxin, levofloxacin, and other fluoroquinolones compared with selected agents of proven efficacy against Listeria monocytogenes. Diagn Microbiol Infect Dis 1994, 20:21\u201325.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11_CR43","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/515003","volume":"27","author":"I Lutsar","year":"1998","unstructured":"Lutsar I, McCracken G, Friedland IR: Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis 1998, 27:1117\u20131129. This outstanding paper reviews the pharmacodynamic parameters of antibiotics used in the treatment of bacterial meningitis.","journal-title":"Clin Infect Dis"},{"key":"11_CR44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/B978-012059517-4\/50006-4","volume-title":"The Quinolones","author":"MK Kim","year":"2000","unstructured":"Kim MK, Nightingale CH: Pharmacokinetics and pharmacodynamics of the fluoroquinolones. In The Quinolones. Edited by Andriole VT. San Diego: Academic Press; 2000:169\u2013202. This review presents a detailed overview of pharmacokinetic and pharmacodynamic aspects of fluoroquinolones."},{"issue":"Suppl 6a","key":"11_CR45","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1016\/0002-9343(91)90311-K","volume":"91","author":"MN Dudley","year":"1991","unstructured":"Dudley MN: Pharmacodynamics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991, 91(Suppl 6a):45S-50S.","journal-title":"Am J Med"},{"key":"11_CR46","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/AAC.41.5.1186","volume":"41","author":"YS Kim","year":"1997","unstructured":"Kim YS, Liu Q, Chow LL, et al.: Trovafloxacin in treatment of rabbits with experimental meningitis caused by high-level resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1997, 41:1186\u20131189.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR47","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/AAC.45.11.3098-3103.2001","volume":"45","author":"V Rodriguez-Cerrato","year":"2001","unstructured":"Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al.: BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2001, 45:3098\u20133103.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR48","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1128\/AAC.45.11.3092-3097.2001","volume":"45","author":"V Rodriguez-Cerrato","year":"2001","unstructured":"Rodriguez-Cerrato V, McCopig CC, Michelow IC, et al.: Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother 2001, 45:3092\u20133097.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR49","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1128\/AAC.42.10.2650","volume":"42","author":"I Lutsar","year":"1998","unstructured":"Lutsar I, Friedland I, Wubbel L, et al.: Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 1998, 42:2650\u20132655.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/jac\/36.6.987","volume":"36","author":"X Meng","year":"1995","unstructured":"Meng X, Pei Y, Nightingale CH, et al.: Determination of the in vivo post-antibiotic effect of ciprofloxacin and rifampicin. J Antimicrob Chemother 1995, 36:987\u2013996.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR51","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1128\/AAC.42.3.659","volume":"42","author":"AA Firsov","year":"1998","unstructured":"Firsov AA, Shevchenko AA, Vostrov SN, Zinner SH: Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insights into a widely used concept. Antimicrob Agents Chemother 1998, 42:659\u2013665.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR52","unstructured":"Hopkins S, Williams D, Dunne M, et al.: A randomized controlled trial of oral or iv trovafloxacin versus ceftriaxone in the treatment of epidemic meningococcal meningitis. Paper presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. September 15\u201318, 1996."},{"key":"11_CR53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00006454-200201000-00004","volume":"21","author":"X Saez-Lorenz","year":"2002","unstructured":"Saez-Lorenz X, McCoig C, Feris J, et al.: Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin J Pediatr Infect Dis 2002, 21:14\u201322. This prospective multicenter study demonstrates that trovafloxacin monotherapy is comparable to the standard regimen in bacterial meningitis.","journal-title":"J Pediatr Infect Dis"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0732-8893(99)00052-8","volume":"35","author":"V Krcmery","year":"1999","unstructured":"Krcmery V, Filka J, Uher J, et al.: Ciprofloxacin in treatment of nosocomial meningitis in neonates and in infants: report of 12 cases and review. Diag Microbiol Infect Dis 1999, 35:75\u201380.","journal-title":"Diag Microbiol Infect Dis"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S0140-6736(86)91242-0","volume":"1","author":"MR Millar","year":"1986","unstructured":"Millar MR, Bransby-Zachary MA, Tompkins DS, et al.: Ciprofloxacin for Pseudomonas aeruginosa meningitis. Lancet 1986, 1:1325.","journal-title":"Lancet"},{"key":"11_CR56","first-page":"215","volume":"25","author":"Z Bhutta","year":"1992","unstructured":"Bhutta Z, Faroqui B, Sturm W: Eradication of a multiple drug resistant Salmonella paratyphi A causing meningitis with ciprofloxacin. J Infect Dis 1992, 25:215\u2013219.","journal-title":"J Infect Dis"},{"key":"11_CR57","first-page":"253","volume":"26","author":"SD Green","year":"1993","unstructured":"Green SD, Ilunga F, Cheesbrough JS, et al.: The treatment of neonatal meningitis due to Gram-negative bacilli with ciprofloxacin: evidence of satisfactory penetration into the cerebrospinal fluid. J Infect Dis 1993, 26:253\u2013256.","journal-title":"J Infect Dis"},{"key":"11_CR58","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1086\/317462","volume":"31","author":"J Lipman","year":"2000","unstructured":"Lipman J, Allworth A, Walis SC: Cerebrospinal penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000, 31:1331\u20131133.","journal-title":"Clin Infect Dis"},{"key":"11_CR59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.42.6.1397","volume":"42","author":"H Schmidt","year":"1998","unstructured":"Schmidt H, Dalhoff A, Stuertz K, et al.: Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother 1998, 42:1397\u20131401.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR60","first-page":"593","volume":"39","author":"C Ostergaard","year":"1998","unstructured":"Ostergaard C, Sorensen TK, Knudsen JD, et al.: Evaluation of moxifloxacin, a new 8-methoxyquinolone for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob Agents Chemother 1998, 39:593\u2013597.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/47.5.701","volume":"47","author":"M Perrig","year":"2001","unstructured":"Perrig M, Acosta F, Cottagnoud M, et al.: Efficacy of gatifloxacin alone and in combination with cefepime against penicillinresistant Streptococcus pneumoniae in a rabbit meningitis model and in vitro. J Antimicrob Chemother 2001, 47:701\u2013704.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR62","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1128\/AAC.44.3.767-770.2000","volume":"44","author":"A Smirnov","year":"2000","unstructured":"Smirnov A, Wellmer A, Gerber J, et al.: Gemifloxacin is effective in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2000, 44:767\u2013770.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR63","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1128\/AAC.46.5.1607-1609.2002","volume":"46","author":"P Cottagnoud","year":"2002","unstructured":"Cottagnoud P, Acosta F, Cottagnoud M, et al.: Gemifloxacin is efficacious against penicillin-resistant and quinoloneresistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002, 46:1607\u20131609.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/jac\/46.2.249","volume":"46","author":"CM Gerber","year":"2000","unstructured":"Gerber CM, Tovar L, Cottagnoud M, et al.: Grepafloxacin against penicillin-resistant pneumococci in the rabbit meningitis model. J Antimicrob Chemother 2000, 46:249\u2013243.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR65","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/AAC.45.11.3098-3103.2001","volume":"45","author":"V Rodriguez-Cerrato","year":"2001","unstructured":"Rodriguez-Cerrato V, Ghaffar F, Saavedra J, et al.: BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 2001, 45:3098\u20133103.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR66","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1128\/AAC.46.6.1760-1765.2002","volume":"46","author":"M Takahata","year":"2002","unstructured":"Takahata M, Yamada H, Morita T, et al.: Evaluation of T-3811ME (BMS-284756), a new des-F(6)-quinolone, for treatment of meningitis caused by penicillin-resistant Streptococcus pneumoniae in rabbits. Antimicrob Agents Chemother 2002, 46:1760\u20131765.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR67","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1128\/AAC.46.1.184-187.2002","volume":"46","author":"P Cottagnoud","year":"2002","unstructured":"Cottagnoud P, Acosta F, Cottagnoud M, et al.: Efficacies of BMS 284756 against penicillin-sensitive, penicillin-resistant, and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2002, 46:184\u2013187.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR68","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1128\/AAC.47.1.211-215.2003","volume":"47","author":"V Rodriguez-Cerrato","year":"2003","unstructured":"Rodriguez-Cerrato V, McCoig C, Saavedra J, et al.: Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci. Antimicrob Agents Chemother 2003, 47:211\u2013215.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR69","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/AAC.43.4.963","volume":"43","author":"D Rodoni","year":"1999","unstructured":"Rodoni D, Haenni F, Gerber CM, et al.: Trovafloxacin in combination with vancomycin against penicillin-resistant pneumococci in the rabbit meningitis model. Antimicrob Agents Chemother 1999, 43:963\u2013965.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR70","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1128\/AAC.44.8.2179-2181.2000","volume":"44","author":"P Cottagnoud","year":"2000","unstructured":"Cottagnoud P, Acosta F, Cottagnoud M, et al.: Synergy between trovafloxacin and ceftriaxone against penicillin-resistant pneumococci in the rabbit meningitis model and in vitro. Antimicrob Agents Chemother 2000, 44:2179\u20132181.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR71","unstructured":"Flatz L, Cottagnoud M, Acosta F, et al.: Ceftriaxone acts synergistically with levofloxacin against penicillin resistant pneumococci in experimental meningitis and reduces levofloxacin-induced resistance in vitro. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. September 27\u201330, 2002."},{"key":"11_CR72","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/AAC.43.7.1651","volume":"43","author":"C Michelet","year":"1999","unstructured":"Michelet C, Leib SL, Bentue-Ferrer D, et al.: Comparative efficacies of antibiotics in a rat model of meningoencephalitis due to Listeria monocytogenes. Antimicrob Agents Chemother 1999, 43:1651\u20131656.","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR73","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/CMR.13.1.144","volume":"13","author":"M van Deuren","year":"2000","unstructured":"van Deuren M, Brandzaeg P, van der Meer JW: Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 2000, 13:144\u2013166.","journal-title":"Clin Microbiol Rev"},{"key":"11_CR74","first-page":"99","volume-title":"The Quinolones","author":"A Philips","year":"2002","unstructured":"Philips A, King A, Shannon K: Comparative in-vitro properties of the quinolones. In The Quinolones. Edited by Andriole VT. San Diego: Academic Press; 2002:99\u2013137. This review presents an excellent summary of the in vitro activity of quinolones."},{"key":"11_CR75","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jac\/40.5.639","volume":"40","author":"A Bauernfeind","year":"1997","unstructured":"Bauernfeind A: Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997, 40:639\u2013651.","journal-title":"J Antimicrob Chemother"},{"key":"11_CR76","volume-title":"Bacterial meningitis","author":"AR Tunkel","year":"2001","unstructured":"Tunkel AR: Bacterial meningitis. Philadelphia: Lippincott Williams & Wilkins; 2001. This outstanding book reviews all aspects of bacterial meningitis including epidemiology, pathophysiology, diagnosis, and treatment."}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-003-0011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-003-0011-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-003-0011-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T05:06:43Z","timestamp":1628917603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-003-0011-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["11"],"URL":"https:\/\/doi.org\/10.1007\/s11908-003-0011-0","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}